Treatment and Prognostic Implications of Strong PD-L1 Expression in Primary Hepatic Sarcomatoid Carcinoma

References

• Wege H , SchulzeK, von FeldenJ, CalderaroJ, ReigM. Rare liver tumors working group of the European Reference Network on Hepatological Diseases (ERN RARE-LIVER). Rare variants of primary liver cancer: fibrolamellar, combined, and sarcomatoid hepatocellular carcinomas. Eur. J. Med. Genet.64(11), 104313 (2021).
   PubMed Web of Science ®Google Scholar
• Zhou C , ZhangX, ZhouKet al. Long-term outcomes and prognosis for patients with sarcomatoid hepatocellular carcinoma. Ann. Transl. Med.10(7), 394 (2022).
   PubMed Web of Science ®Google Scholar
• Liao SH , SuTH, JengYMet al. Clinical manifestations and outcomes of patients with sarcomatoid hepatocellular carcinoma. Hepatology69(1), 209–221 (2019).
   PubMed Web of Science ®Google Scholar
• Sung CO , ChoiH, LeeKW, KimSH. Sarcomatoid carcinoma represents a complete phenotype with various pathways of epithelial mesenchymal transition. J. Clin. Pathol.66(7), 601–606 (2013).
   PubMed Web of Science ®Google Scholar
• Wang JP , YaoZG, SunYWet al. Clinicopathological characteristics and surgical outcomes of sarcomatoid hepatocellular carcinoma. World J. Gastroenterol.26(29), 4327–4342 (2020).
   PubMed Web of Science ®Google Scholar
• Lu J , XiongXZ, LiFYet al. Prognostic significance of sarcomatous change in patients with hepatocellular carcinoma after surgical resection. Ann. Surg. Oncol.22(Suppl. 3), S1048–S1056 (2015).
   PubMedGoogle Scholar
• Lu J , ZhangJ, XiongXZet al. Primary hepatic sarcomatoid carcinoma: clinical features and prognosis of 28 resected cases. J. Cancer Res. Clin. Oncol.140(6), 1027–1035 (2014).
   PubMed Web of Science ®Google Scholar
• Zhang H , ChaiS, ChenLet al. MRI features of hepatic sarcomatoid carcinoma different from hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Front. Oncol.11, 611738 (2021).
   PubMed Web of Science ®Google Scholar
• Ma S , LiC, MaY, WangX, ZhangD, LuZ. A retrospective study on the clinical and pathological features of hepatic sarcomatoid carcinoma: fourteen cases of a rare tumor. Medicine (Baltimore)101(31), e30005 (2022).
   PubMed Web of Science ®Google Scholar
• Obara K , MatsumotoN, OkamotoMet al. Insufficient radio frequency ablation therapy may induce further malignant transformation of hepatocellular carcinoma. Hepatol. Int.2(1), 116–123 (2008).
   PubMed Web of Science ®Google Scholar
• Yu Y , ZhongY, WangJ, WuD. Sarcomatoid hepatocellular carcinoma (SHC), a case report. World J. Surg. Oncol.15(1), 219 (2017).
   PubMedGoogle Scholar
• Koo HR , ParkMS, KimMJet al. Radiological and clinical features of sarcomatoid hepatocellular carcinoma in 11 cases. J. Comput. Assist. Tomogr.32(5), 745–749 (2008).
   PubMed Web of Science ®Google Scholar
• Leng Q , XiangXI, TangY, YangY, QiuLI. Primary hepatic sarcomatoid carcinoma: a case report. Exp. Ther. Med.10(3), 1145–1148 (2015).
   PubMed Web of Science ®Google Scholar
• Yoshida N , MidorikawaY, KajiwaraTet al. Hepatocellular carcinoma with sarcomatoid change without anticancer therapies. Case. Rep. Gastroenterol.7(1), 169–174 (2013).
   PubMedGoogle Scholar
• Morisue R , KojimaM, SuzukiTet al. Sarcomatoid hepatocellular carcinoma is distinct from ordinary hepatocellular carcinoma: clinicopathologic, transcriptomic and immunologic analyses. Int. J. Cancer149(3), 546–560 (2021).
   PubMed Web of Science ®Google Scholar
• Yoshuantari N , JengYM, LiauJY, LeeCH, TsaiJH. Hepatic sarcomatoid carcinoma is an aggressive hepatic neoplasm sharing common molecular features with its conventional carcinomatous counterparts. Mod. Pathol.36(1), 100042 (2023).
   PubMed Web of Science ®Google Scholar
• Hu S , WuX, ZhouBet al. IMP3 combined with CD44s, a novel predictor for prognosis of patients with hepatocellular carcinoma. J. Cancer Res. Clin. Oncol.140(6), 883–893 (2014).
   PubMed Web of Science ®Google Scholar
• Gao Y , YangM, JiangZet al. IMP3 expression is associated with poor outcome and epigenetic deregulation in intrahepatic cholangiocarcinoma. Hum. Pathol.45(6), 1184–1191 (2014).
   PubMed Web of Science ®Google Scholar
• Kythreotou A , SiddiqueA, MauriFA, BowerM, PinatoDJ. PD-L1. J. Clin. Pathol.71(3), 189–194 (2018).
   PubMedGoogle Scholar
• Vij M , VeerankuttyFH, RajuLPet al. Frequent expression of PD-L1 in lymphocyte-rich hepatocellular carcinoma: a report of 4 cases. Ann. Diagn. Pathol.66, 152172 (2023).
   PubMed Web of Science ®Google Scholar
• Calderaro J , RousseauB, AmaddeoGet al. Programmed death ligand 1 expression in hepatocellular carcinoma: relationship with clinical and pathological features. Hepatology64, 2038–2046 (2016).
   PubMed Web of Science ®Google Scholar
• Luo C , XinH, YinDet al. Characterization of immune infiltration in sarcomatoid hepatocellular carcinoma. Aging (Albany NY)13(11), 15126–15138 (2021).
   PubMedGoogle Scholar
• Hwang S , LeeSG, LeeYJet al. Prognostic impact of sarcomatous change of hepatocellular carcinoma in patients undergoing liver resection and liver transplantation. J. Gastrointest. Surg.12(4), 718–724 (2008).
   PubMed Web of Science ®Google Scholar
• Zhu SG , LiHB, YuanZNet al. Achievement of complete response to nivolumab in a patient with advanced sarcomatoid hepatocellular carcinoma: a case report. World J. Gastrointest. Oncol.12(10), 1209–1215 (2020).
   PubMed Web of Science ®Google Scholar
• Goto Y , TajiriK, TanakaSet al. A ruptured sarcomatoid hepatocellular carcinoma treated with combined immunotherapy. Clin. J. Gastroenterol.16(2), 244–249 (2023).
   PubMed Web of Science ®Google Scholar
• Queiroz MM , MunhozRR, MasottiCet al. Durable response to nivolumab in a patient with hepatic sarcomatoid carcinoma: evolutive characterization of genomic and immunohistochemical PD-L1 expression findings. JCO Precis. Oncol.6, e2200163 (2022).
   PubMed Web of Science ®Google Scholar
• Vij M , CalderaroJ. Pathologic and molecular features of hepatocellular carcinoma: an update. World J. Hepatol.13(4), 393–410 (2021).
   PubMed Web of Science ®Google Scholar
• Calderaro J , CouchyG, ImbeaudSet al. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. J. Hepatol.67, 727–738 (2017).
   PubMed Web of Science ®Google Scholar
• Kodama T , NewbergJY, KodamaMet al. Transposon mutagenesis identifies genes and cellular processes driving epithelial–mesenchymal transition in hepatocellular carcinoma. Proc. Natl Acad. Sci U S A113(24), e3384–e3393 (2016).
   PubMed Web of Science ®Google Scholar
• Zhang C , FengS, TuZet al. Sarcomatoid hepatocellular carcinoma: from clinical features to cancer genome. Cancer Med.10(18), 6227–6238 (2021).
   PubMed Web of Science ®Google Scholar
• Menendez D , IngaA, ResnickMA. The expanding universe of p53 targets. Nat. Rev. Cancer.9(10), 724–737 (2009).
   PubMed Web of Science ®Google Scholar
• Hernández Borrero LJ , El-DeiryWS. Tumor suppressor p53: biology, signaling pathways, and therapeutic targeting. Biochim. Biophys. Acta Rev. Cancer1876(1), 188556 (2021).
   PubMed Web of Science ®Google Scholar
• Fon Tacer K , MontoyaMC, OatleyMJet al. MAGE cancer-testis antigens protect the mammalian germline under environmental stress. Sci. Adv.5(5), eaav4832 (2019).
   PubMed Web of Science ®Google Scholar
• Li R , GongJ, XiaoCet al. A comprehensive analysis of the MAGE family as prognostic and diagnostic markers for hepatocellular carcinoma. Genomics112(6), 5101–5114 (2020).
   PubMed Web of Science ®Google Scholar
• Tamura R . Current understanding of neurofibromatosis type 1, 2, and schwannomatosis. Int. J. Mol. Sci.22(11), 5850 (2021).
   PubMed Web of Science ®Google Scholar